Flash Finance

Hamps Bio Ltd544312Corporate

Latest results: Mar 2026 5 quarters of data
Consolidated Standalone
—
MCap —
Live price not available
Hamps Bio Ltd — Stock analysis & AI research Hamps Bio Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹5 Cr
Sales · Mar 2026
+44.7% YoY
₹-0 Cr
Operating Profit · Mar 2026
-131.8% YoY
-1.5%
OPM % · Mar 2026
-121.4% YoY
₹-0 Cr
Net Profit · Mar 2026
-1633.3% YoY
₹-0.53
EPS · Mar 2026
-1866.7% YoY

📝 Hamps Bio Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Hamps Bio Ltd reported revenue of ₹5 crore for the quarter ended March 2026 (Q4 FY26), up 44.7% from ₹3 crore in the same quarter last year.

The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.53.

Operating profit stood at ₹-0 crore — an operating margin (OPM) of -1.5%, compared with 7.0% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹9 crore with a net loss of ₹1 crore.

Shareholding pattern

As of Mar 2026, promoters held 71.99%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.00%, public shareholders 28.01% of Hamps Bio Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
N/A
Current Price ?
N/A
P/E ?
N/A
Industry P/E ?
N/A
P/B ?
N/A
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
N/A
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹9 Cr
OPM ?
1.3%
Profit after tax (TTM) ?
₹-1 Cr
EPS (TTM) ?
₹-0.76
ROCE ?
-2.8%
ROE ?
-8.1%
ROA ?
-4.3%
Growth
Sales — latest qtr ?
₹5 Cr
PAT — latest qtr ?
₹-0 Cr
YoY qtr sales growth ?
44.7%
YoY qtr profit growth ?
-1,633.3%
Sales growth (3y) ?
15%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹6 Cr
Debt to Equity ?
0.78
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
71.99%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
N/A
Return 6 months ?
N/A

🗓️ Quarterly results (5 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 34345 +44.7% —
Operating Profit 1100-0 -131.8% —
Other Income 00000 +314.3% —
Interest 00000 +116.7% —
Depreciation 00001 +168.4% —
Profit Before Tax 000-0-0 -1150.0% —
Net Profit 000-0-0 -1633.3% —
EPS 0.590.430.03-0.23-0.53 -1866.7% —
OPM % 16.5% 15.5% 7.0% 4.5% -1.5% -121.4% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 1.501.964.368.71 +99.8%
Reserves -0.141.384.44-0.53 -111.9%
Borrowings 1.741.052.976.40 +115.5%
Other Liabilities 0.860.730.970.64 -34.0%
Total Liabilities 3.965.1212.7415.22 +19.5%
Fixed Assets 2.612.522.437.19 +195.9%
CWIP -0.00-0.003.381.08 -68.0%
Investments -0.00-0.00-0.002.04 —
Other Assets 1.352.606.934.91 -29.1%
Total Assets 3.965.1212.7415.22 +19.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1.23-0.29-1.77-0.43 +75.7%
Cash from Investing Activity -0.75-0.37-6.20-2.86 +53.9%
Cash from Financing Activity -0.480.678.003.23 -59.6%
Net Cash Flow -0.000.010.04-0.06 -250.0%
Free Cash Flow 0.44-0.65-5.49-3.65 +33.5%
CFO/OP 141%-12%-216%-391% -81.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 49.7155.7665.1251.84 -20.4%
Inventory Days 75.03264.09452.45281.84 -37.7%
Days Payable 103.4260.12114.0639.27 -65.6%
Cash Conversion Cycle 21.32259.73403.51294.40 -27.0%
Working Capital Days -58.2255.20124.2260.83 -51.0%
ROCE % 17.56%21.36%6.68%-2.81% -142.1%

👥 Shareholding (latest 4 periods)

Metric Dec 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 71.99%71.99%72.00%71.99% -0.0%
FIIs 0.18%0.00%0.00%0.00% —
DIIs 0.05%0.00%0.00%0.00% —
Public 27.78%28.01%28.01%28.01% +0.0%
No. of Shareholders 589410395395 +0.0%

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.
❓ Frequently asked questions
What was Hamps Bio Ltd's revenue in Q4 FY26?
Hamps Bio Ltd reported revenue of ₹5 crore for the quarter ended March 2026 (Q4 FY26), up 44.7% from ₹3 crore in the same quarter last year.
What was Hamps Bio Ltd's net profit in Q4 FY26?
The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.53.
Who owns Hamps Bio Ltd? (shareholding pattern)
As of Mar 2026, promoters held 71.99%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.00%, public shareholders 28.01% of Hamps Bio Ltd.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI